Warnex Inc.

Warnex Inc.

May 15, 2006 07:00 ET

Warnex products to be distributed by FOSS U.K.

LAVAL, QC, May 15 - Warnex Inc. (TSX: WNX) today announced it has
finalized an agreement with FOSS U.K. Ltd. to distribute and market the
Warnex™ Rapid Pathogen Detection System in the United Kingdom and Ireland.

"We are pleased to expand our relationship with FOSS to include
distribution in the UK and Ireland," said Mark Busgang, President and CEO.
"The 11 systems sold since March 2004 speaks to FOSS Italia's success with the
sale of the Warnex System in Italy and we are looking forward to extending
this progress in the UK and Ireland."

FOSS U.K. is a wholly owned subsidiary of FOSS A/S based in Denmark.
Founded in 1956, FOSS (www.foss.dk) is a leading international provider of
analytical solutions for the food, agricultural, chemical and pharmaceutical
industries. It has offices in 21 countries and more than 1,100 employees.
Based in Warrington, FOSS U.K. employs 42 people.

"The Warnex Rapid Pathogen Detection System has provided clear and
consistent benefits to FOSS Italia clients. This palpable success has
reinforced our belief in the value of this Warnex product", said Chris
Ravenscroft, Managing Director of FOSS U.K. "As such, we hope to replicate
this success throughout our customer network in the United Kingdom and
Ireland."

FOSS U.K. will replace Warnex's previous distributor for the U.K., Don
Whitley Scientific Limited.

The Warnex Rapid Pathogen Detection System uses cutting-edge DNA-based
technology to rapidly and accurately determine the presence of pathogens in a
sample. The system allows for the simultaneous detection of multiple pathogens
and processing of samples within 3 to 48 hours, a significant improvement over
traditional microbiology tests that currently require 5 to 7 days.

About Warnex

Warnex (www.warnex.ca) is a biotechnology company devoted to protecting
public health by providing advanced diagnostic products and science-based
services to the agri-food, pharmaceutical and healthcare sectors. Warnex's
genomics-based technology offers a versatile detection platform that produces
accurate results rapidly, using Real-Time PCR technology combined with unique
genetic markers and software. With a focus on pathogen detection in food, our
development pipeline also includes applications in GMO testing and meat
speciation, as well as in the detection of viruses, yeasts and moulds.
Warnex's analytical, bioanalytical, and medical laboratory service groups
offer a variety of quality control services, method development and
validation, contract R&D, bioavailability and bioequivalence studies for
clinical trials, and medical laboratory testing.

Warnex is a trademark of Warnex Inc., Laval, Quebec.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS Certain statements contained
in this news release are forward-looking and are subject to numerous risks and
uncertainties, known and unknown. For information identifying known risks and
uncertainties, relating to the early commercialization of Warnex products,
intellectual property and licensing, R&D of new Warnex products, manufacturing
and laboratory facilities, suppliers, key employees, key customers, financial
resources and credit risk, government regulations, foreign currency risk and
volatility of share price, and other important factors that could cause actual
results to differ materially from those anticipated in the forward-looking
statements, please refer to the heading Risks and Uncertainties in the
Management's Discussion and Analysis for the first quarter ended March 31,
2006, which can be found at www.sedar.com. Consequently, actual results may
differ materially from the anticipated results expressed in these forward-
looking statements.

Contact Information